Wearable sensor aims to tame dangerous drug side effect for cancer patients
NCT ID NCT06083038
Summary
This study aims to better understand and manage high blood sugar, a common side effect of the breast cancer drug alpelisib. Fifteen patients with metastatic breast cancer will wear a continuous glucose monitor (CGM) for at least three months while taking the drug. The goal is to track blood sugar patterns closely to help prevent and control this side effect, improving patient safety during cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HealthPartners Cancer Research Center
Saint Louis Park, Minnesota, 55426, United States
Conditions
Explore the condition pages connected to this study.